Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.
Alzheon has raised $78.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2026.
Alzheon's investors include Ally Bridge Group, National Institute on Aging, Scott H. Cohen, Alerce Medical Technology Partners.
Alzheon is headquartered in Framingham, United States.
Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.
Alzheon is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alzheon — Funding & Investors." VCBacked, September 10, 2026, https://www.vcbacked.co/company/alzheon. Accessed November 14, 2026.
VCBacked. (2026). Alzheon — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/alzheon
{{cite web |title=Alzheon — Funding & Investors |url=https://www.vcbacked.co/company/alzheon |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Alzheon? Request a listing update